Sanofi Consumer Healthcare India Limited has announced robust financial results for the quarter and year ended December 31, 2025, demonstrating strong operational performance across key metrics. The company published its audited financial results in Business Standard and Sakal newspapers on February 27, 2026.

Strong Quarterly Performance

The company delivered exceptional growth in Q4 FY25, with significant improvements across all major financial parameters. The quarterly results showcase the company's ability to maintain momentum in a competitive healthcare market.

Annual Financial Highlights

For the full financial year FY25, Sanofi Consumer Healthcare India maintained its growth trajectory with consistent performance improvements. The annual results reflect the company's strategic initiatives and market positioning in the consumer healthcare segment.

Sequential Quarter Performance

Comparing Q4 FY25 with the previous quarter (Q3 FY25), the company showed continued momentum with total income increasing from ₹2,369 million to ₹2,556 million, representing a 7.89% sequential growth. Net profit after tax also improved from ₹629 million in Q3 FY25 to ₹665 million in Q4 FY25.

Dividend Recommendation and Corporate Actions

The Board of Directors has recommended a final dividend of ₹75 per equity share of ₹10 face value for the year ended December 31, 2025. This dividend recommendation is subject to approval by shareholders at the upcoming Annual General Meeting.

Regulatory Compliance and Governance

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and were reviewed by the Audit Committee before approval by the Board of Directors on February 25, 2026. The company maintains its commitment to transparency and regulatory compliance under SEBI listing requirements.

Sanofi Consumer Healthcare India Limited announced the designation of two senior executives as Senior Management Personnel following a board meeting held on February 25, 2026. The decision reflects the company's strategic focus on strengthening its leadership structure across key operational areas.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination & Remuneration Committee, designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. The board meeting commenced at 2:00 p.m. and concluded at 5:20 p.m.

The company made this disclosure pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements.

Senior Management Personnel Details

Ms. Nupur Gurbaxani - Brand & Innovation Leadership

Ms. Gurbaxani serves as Director of Brand & Innovation and has been instrumental in driving the company's brand penetration turnaround since joining in July 2024. She brings a consumer-centric approach with sharp insights, innovative campaigns, and digital-first strategies.

An alumna of NMIMS, she possesses over 18 years of extensive experience across leading consumer and healthcare companies including Godrej Consumer Products, Novartis, and Abbott Nutrition. Her expertise positions her to play a critical role in the company's brand transformation and future growth initiatives.

Mr. Viral Shah - Manufacturing Excellence

Mr. Shah holds the position of Director of External Manufacturing and has been driving key infrastructure development initiatives since joining in May 2024. His focus areas include developing partnerships and capabilities to support the company's "Make In India" strategy across product lines.

A graduate of KJ Somaiya Institute of Management, he brings over 20 years of manufacturing and pharmaceutical industry experience from prominent organizations including Torrent, Ranbaxy Laboratories, Merck & Co., and Bayer. His strategic insight and industry expertise are expected to strengthen manufacturing capabilities and accelerate export growth from India.

Strategic Implications

The designation of these executives as Senior Management Personnel underscores Sanofi Consumer Healthcare India's commitment to strengthening its operational leadership. Both appointments align with the company's strategic priorities in brand innovation and manufacturing excellence, positioning the organization for enhanced market performance and growth acceleration. The formal notification to stock exchanges demonstrates the company's adherence to regulatory compliance and transparency standards.